Emtricitabine(em tra cye’ tah ben)
Emtriva
PREGNANCY CATEGORY B
Drug Classes
Anti-HIV drug
Antiviral
Nucleoside reverse transcriptase inhibitor
Therapeutic Actions
HIV-1 reverse transcriptase inhibitor; competes with a natural substrate and is incorporated into the viral DNA, leading to chain termination.
Indications
In combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults and children
Contraindications and Cautions
Contraindicated with allergy to any components of the product; lactation (HIV-infected mothers are discouraged from breast-feeding); concurrent use of lamivudine, Atripla, Truvada.
Use cautiously with pregnancy; hepatic impairment; signs of lactic acidosis, risk factors for lactic acidosis including female gender and obesity; infection with hepatitis B virus; impaired renal function.
Available Forms
Capsules—200 mg; oral solution—10 mg/mL
Dosages
Adults
200 mg daily PO, with or without food or 240 mg (24 mL) oral solution/day PO.
Pediatric patients 3 mo–17 yr
6 mg/kg PO once daily to a maximum 240 mg (24 mL) oral solution; children weighing more than 33 kg and able to swallow a capsule may take one 200-mg capsule/day PO.
Pediatric patients up to 3 mo
3 mg/kg oral solution PO once daily
Patients with renal impairment
For dialysis patients, 200 mg PO every 96 hr. For renally impaired patients, use these dosages:
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
